Abstract: A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.

Abstract: Various embodiments set forth high-resolution liquid crystal displays and components thereof. In some embodiments, light emitted by a high-resolution green color liquid crystal display is combined, via a combiner, with light emitted by at least one lower-resolution red and blue color liquid crystal display. The red and blue color display(s) may include a single display or two displays positioned on opposing sides of the combiner. The combiner may be a dichroic or polarization-based combiner. Combined light from the green color display and the red and blue color display(s) is passed through collimating optics, such as a pancake lens or a Fresnel lens, toward a viewer's eye.

Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 × 105 to 5.0 × 106 of CAR-T cells per kilogram of the subject’s mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.